| Virginia Commonwealth University Patent applications |
| Patent application number | Title | Published |
|---|
| 20110313028 | SUPPRESSOR OF AP-1 - Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated by SARI, for targeting therapeutic molecules in tumors is also provided. | 12-22-2011 |
| 20110060578 | COMPREHENSIVE MODELING OF THE HIGHLY NETWORKED COAGULATION-FIBRINOLYSIS-INFLAMMATORY-IMMUNE SYSTEM - An agent-based modeling system (ABMS) is employed to quantitatively analyze individual components of each system of the coagulation-immune/inflammatory-fibrinolysis system at every point of simulation. ABMS is a dynamic modeling and simulation tool that allows the study of dynamic non-linear networked systems. ABMS represents a non-reductionist approach of studying the biologic process as a whole, while retaining information at the level of an individual component. | 03-10-2011 |
| 20110009291 | METHODS AND COMPOSITIONS FOR INCREASING MEMBRANE PERMEABILITY - Methods and compositions for increasing membrane permeability are provided. One aspect provides protein resulting from a fusion between a membrane-active peptide and second peptide. Nucleic acids and vectors encoding the pore forming fusion proteins are also provided. | 01-13-2011 |
| 20100291058 | Sealants for Skin and Other Tissues - The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants. | 11-18-2010 |
| 20090155342 | Mineral technologies (MT) for acute hemostasis and for the treatment of acute wounds and chronic ulcers - Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided. | 06-18-2009 |
| 20090149748 | Portable Pulmonary Injury diagnostic Devices And Methods - Lung injury such as pneumothorax now can be diagnosed reliably, portably and quickly. Vibro-acoustic waves are sent through the chest and the resulting wave is measured. By analyzing attenuation characteristics determined by the geometry of the chest structures, a determination can be made of whether the patient's pleural space is healthy, contains air (pneumothorax) or contains fluid (hemothorax). | 06-11-2009 |
| 20090104221 | RAPID GENERATION OF T CELL-INDEPENDENT ANTIBODY RESPONSES TO T CELL-DEPENDENT ANTIGENS - The present invention comprises the use of follicular dendritic cells (FDCs) or FDC-like cells to generate FDC-dependent, but T cell-independent, B cell responses to T cell-dependent antigens, with antigen-specific and polyclonal antibody production in ˜48 h. In another embodiment, a germinal center (GC) lymphoid tissue equivalent (LTE) was used to generate antigen-specific IgM, followed by switching to IgG. The GC LTE model can be used in vaccine assessment. Dual forms of immunogen were used in the GC LTE and in vivo. Dual immunogens resulted in rapid, specific IgM responses and enhanced IgG responses. This vaccine design approach can be used, for example, to provide rapid IgM protection (˜24-48 h) and high-affinity IgG more quickly in people moving to areas with endemic disease, or in people with T cell insufficiencies, who can be immunized to rapidly generate protective IgM. | 04-23-2009 |
| 20080280781 | Methods and Compositions for Increasing Membrane Permeability - Methods and compositions for increasing membrane permeability are provided. One aspect provides protein resulting from a fusion between a membrane-active peptide and second peptide. Nucleic acids, and vectors encoding the, pore forming fusion proteins are also provided. | 11-13-2008 |
